Economics of Rotavirus Gastroenteritis and Vaccination in Europe: What Makes Sense? by NC DOCKS at Appalachian State University & Rheingans, Richard
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ 
Economics of Rotavirus Gastroenteritis and Vaccination in 
Europe: What Makes Sense?
By: Richard D. Rheingans, Johan Heylen, harm S, and Carlo Giaquinto
Abstract
Rotavirus is a major cause of gastroenteritis in children throughout Europe and the world. In 
addition to causing morbidity and mortality in children, rotavirus gastroenteritis (RVGE) 
creates a major economic burden on health care systems and families in Europe. The costs of 
hospital admissions for RVGE and nosocomial infections generate significant medical 
treatment costs throughout the region. Less information is available on the costs associated 
with less severe episodes and the costs borne by families, including lost time from work. The 
availability of rotavirus vaccines presents an effective opportunity to prevent RVGE and these 
associated eco-nomic costs, as well as providing protection to each child and hence benefiting 
the child’s family. The adoption of rotavirus vaccine by health authorities in Europe will 
require a comparison of the costs and benefits. Economic evaluations that compare the costs of 
vac-cination to the economic benefits of rotavirus vaccination will provide an estimate of its 
financial impact on health care systems and society. However, to provide a complete picture, 
economic evaluations of rotavirus vaccines will need to account for both the reduced costs and 
the reduced morbidity from prevented RVGE. Cost-effectiveness analyses based on quality-
adjusted life years (QALYs) provide a systematic approach for assessing vaccination as a health 
investment, comparing the incremental costs associated with rotavirus vaccination and the 
reduced morbidity and mortality. QALYs provide a standardized approach for quantifying and 
comparing reductions in health-related quality of life and premature mortality. Although 
methodologic limitations exist in applying the QALY approach to childhood vaccines, their 
use in cost effective-ness analyses allows decision makers to consider the full health benefits of 
rotavirus and other vaccines.
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Rotavirus (RV) infection is the single most important causeof diarrheal illness in small children in developed and
developing countries. Gastrointestinal infections in children
have a wide range of impacts on their families and society,
including increased medical expenditures, lost productivity,
other costs to households for the care of children, and pain
and suffering caused to children and their families.
As effective rotavirus vaccines become available, pol-
icy makers will have to make decisions regarding the relative
costs and benefits of vaccination in addition to considering its
clinical effectiveness. In doing so, they must systematically
consider the economic burden of disease, the impact of
vaccination on health and economic outcomes and the net
costs of vaccination and compare the costs of vaccination to
the health benefits.
The purpose of this article is to review the existing data
on the economics of rotavirus gastroenteritis (RVGE) in
Europe and suggest the types of economic evaluations that
will be useful in assessing the merits of vaccination. In
particular, it will address how economic evaluation can be
used to assess the value of vaccination as a health investment
through cost effectiveness analyses using health improvement
measures such as quality-adjusted life years (QALYs).
ECONOMIC IMPACT OF RVGE IN EUROPE
Types of Costs. RVGE generates a variety of costs for the
health care system (direct medical costs), families of those
infected (nonmedical direct costs) and society as a whole
(indirect costs). Medical costs relate to the costs of office
visits, emergency room visits and inpatient stays. The costs
include laboratory, professional services, medication and
other treatments. In Europe, because the existence of National
Health Services, few of these costs are borne by affected
families; more typically, they create a burden for the health
care system of the country.
Nonmedical direct expenses include the out-of-pocket
expenses paid by households that are not related to medical
care, including additional liquids, additional diapers, addi-
tional costs of child care and the costs of traveling to receive
medical care. These costs are borne primarily by the families
of children with RVGE.
Besides the emotional impact of disease on children
and their families, moderate to severe episodes of RV diar-
rhea also result in significant societal and household costs
because of lost work time, often referred to as indirect costs.
These costs are incurred as parents are forced to stay home
from work to care for sick children. This lost time from work
results in a societal cost, because of the reduction in labor
productivity. It can also result in an economic impact on
individual households if parents are self-employed or other-
wise lose wages as a result of their absence. In addition to the
lost time from paid employment, RVGE can also result in
time lost from other productive activities (such as household
work) and leisure activities. These activities also have an
economic value to society and can be included in estimates of
indirect costs, but their economic value is difficult to measure.
Costs of RVGE Hospitalization. Empirical estimates are
available for some of these costs resulting from RV hospi-
talizations and outpatient visits in different European coun-
tries. Studies of medical costs of hospital admissions for
RVGE have been published for Austria,1 Scotland,2 Spain,3
Ireland,4 Sweden5 and England6,7 (Table 1). The study by
Fruhwirth et al1 estimates the cost of community-acquired
cases resulting in medical visits for RVGE (hospital or
office). Studies of the burden of outpatient visits and hospital
admissions for RVGE are based on estimates of incidence
and mean cost per case. Most of the studies above focus on
the direct medical costs associated with treatment and thus
use health care system perspective (or centralized provider
such as a national health system).
The studies differ in their approaches. Some2,3,5 use
national surveillance data on the incidence of RV hospital-
izations combined with standard medical cost estimates
(based on bed-day costs or reimbursement rates) to estimate
national economic burden. Others1,6,7 use detailed cost data
for specific communities or facilities to estimate a cost per
case. The former method provides more representative na-
tional estimates but the latter provides a more detailed esti-
mate of costs. Differences in population size, methods and
primary outcomes make it difficult to compare results. How-
ever, the estimated direct medical cost of RVGE hospitaliza-
tion is over ranges from 1 million euros to 10 million euros
TABLE 1. Studies of Economic Burden of Rotavirus Gastroenteritis in Europe
Author Country Events Included Costs Included Key Findings Comments
Cowden,2 2001 Scotland Hospitalizations Medical £275,000 to £835,000
direct medical cost per
year for community-
acquired RVGE;
hospitalization
Based on national admissions
and laboratory surveillance
data. Cost based on
average bed-day cost
Fruhwirth,1 2001 Austria Community-acquired
hospitalizations
and nosocomial
infections
Medical, nonmedical
direct, indirect
€7.2 million direct medical
cost per year for
community acquired
RVGE; €6.2 million direct
medical cost per year for
NRV
Based on community cohort
study
Gil,3 2004 Spain Hospitalizations Medical €3.6 million direct medical
cost per year for
community-acquired
RVGE; hospitalization
Based on national admissions
and laboratory surveillance
data. Cost based on
average bed-day cost
Harrington,4 2003 Ireland Community-acquired
hospitalizations
and nosocomial
infections
Medical €1216 medical cost per
community-acquired
hospitalization; €600
medical cost per NRV.
NRV accounts for 32% of
RVGE hospital cost
Prospective study in 2
pediatric hospitals
Johansen,5 1999 Sweden Hospitalization Medical $1.8–2 million direct
medical cost per year for
community-acquired
RVGE hospitalization
Based on national admissions
and laboratory surveillance
data. Cost based on
average bed-day cost
Noel,6 1994 England Hospitalizations Medical Estimated £6.3 million
direct medical cost per
year in England and
Wales
2 yr study of patients
admitted to a pediatric
hospital for RVGE
Piednoir,8 2003 France Nosocomial infections Medical €1930 additional direct
medical cost per NRV case
Case-control prospective
study in one hospital. Cost
of NRV based on additional
days hospitalized
Takala,9 1998 Finland All RVGE Medical, nonmedical,
and indirect
$260.28 total cost per case of
RVGE in placebo group.
Direct medical costs
account for 89% of costs in
placebo group. 95%
reduction in costs among
vaccinated children
Costs estimated for placebo
and vaccine arms of a RCT
Roberts,7 2003 England Community,
outpatient and
hospitalized cases
Medical, nonmedical
direct, indirect
£18.2 million per year total
societal costs; £11.1
million per year
productivity losses; £5.1
million per year direct
medical cost
Estimates of costs from all
intestinal infectious
disease. Based on
community cohort study
in a number of countries. Only the studies by Fruhwirth et al1
and Roberts et al7 include an estimate of the indirect costs
associated with time lost from work and other direct expenses
for families. Studies that include these additional costs are
using the societal perspective. Estimates of indirect costs
require surveys of a representative sample of parents of
children with RVGE of different severities. Fruhwirth esti-
mated that these family expenses accounted for 12% (30
euros) of the total societal cost of a community-acquired
rotavirus infection resulting in a medical visit, and Roberts et
al estimate that 61% of all RVGE costs are indirect.
Other RVGE Costs. Although estimates of the costs of hos-
pitalization for RVGE exist in a number of countries, several
other types of RVGE cost-generating events are less well-
studied. These events include outpatient visits, nosocomial
infections, outbreaks in elderly care facilities and community-
treated cases. To fully assess the economic burden of RVGE,
it is important to consider the economic impact of these
potentially important cost-generating events as well. The
economic burden of nosocomial rotavirus infection is dealt
with in the article by Gleizes et al10 in this supplement.
There are few studies of the costs of outpatient visits for
RVGE, in part because of the lack of epidemiologic estimates
of the incidence of outpatient visits. Roberts et al7 have
estimated the costs of cases of intestinal infections (including
RVGE) treated by general practitioners in England. In addi-
tion to estimating the costs of treatment, they also calculate
the nonmedical direct costs for affected families and time lost
from work. The same study also estimates the costs for
community diarrheal cases that do not result in treatment at a
formal facility. Although the average cost for these cases (all
causes) may be relatively low (£34.31 per case, primarily
from lost work), their cumulative costs on affected families
(through over-the-counter medication, supplies and time lost
from work) could be significant.
Several studies have documented that community-ac-
quired hospitalization for RV can result in significant hospi-
tal-acquired cases among those children admitted for other
causes. The estimation of the economic consequences of
these infections is challenging.1,4,8 In addition to requiring
the estimation of the number or rate of new RV cases, it is
essential to estimate the additional health care resource costs
(or others) associated with hospital-acquired RV infection,
usually based on the estimated increase in length of stay. This
is particularly challenging because children with longer stays
are more likely to be affected, making it difficult to determine
the extent to which the hospital-acquired infection causes an
increase in stay (rather the reverse). Piednoir et al8 and
Harrington et al4 estimated the additional costs by matching
cases with control patients with similar characteristics in
France and Ireland, respectively. In the former study, noso-
comial RV (NRV) infection resulted in a mean excess stay of
almost 5 days, with an associated direct medical cost of
1900 euros.8 In the study conducted in 2 pediatric hospitals
in Ireland, it was estimated that NRV accounted for 27% of
all RV hospitalizations (with a mean excess cost of 600
euros) and approximately one-fourth of all medical costs
associated with RV hospitalization.4 Although both studies
estimated the additional bed-days due to NRV through
matching of patients, they used a different approach to eval-
uate this end point. However, by matching patients at the time
of developing the RV infection (rather than at initial admis-
sion),4 the possible biases related the possible association
between the length of hospitalization and the risk of devel-
oping RVGE.
Several questions must be addressed to assess the
relative quality of the studies aiming to assess the economic
burden of RVGE. Is disease incidence based on representa-
tive national data or individual facilities? Are case definitions
sufficiently including all events where RVGE results in in-
creased resource utilization and cost? Are mean medical costs
estimated accurately; in particular were the increases in
resource utilization caused by RVGE (length of stay, diag-
nostics and medications) appropriately estimated? Are esti-
mates of productivity losses and nonmedical direct costs
based on a prospective sample of caregivers? These factors
will affect the accuracy, representativeness and completeness
of the estimates and often limit the significance of the studies.
Finally RV hospitalizations may have other costs asso-
ciated with hospitalization that are difficult to quantify. To
control hospital-acquired cases, infection control measures
are typically instituted, although these costs may not be fully
captured by per diem hospital charges. In addition to the costs
associated with individual hospital acquired cases, Lopman et
al11 have shown that gastroenteritis outbreaks in hospital
wards in England and Wales can generate costs as a result of
units being closed to new admissions to control infections. In
addition, the strong seasonality of RV infection (sometimes
corresponding to the peak of respiratory syncytial virus as
well) may require increased capacity in hospital wards that is
otherwise underutilized.
One of the limitations of economic burden studies is
that they often include only a portion of the total costs
associated with RVGE. Important cost-generating events
(Fig. 1), such as outpatient visits, cases seeking informal care
and nosocomial cases, may be left out because of insufficient
epidemiologic information. Similarly important cost catego-
ries (most notably productivity losses and nonmedical direct
expenses) may be overlooked because of the methodologic
difficulties in measuring them such as the need for prospec-
tive surveys of caregivers (Fig. 1). These factors can contrib-
ute to a systematic underestimation of the true cost of illness.
Cost-generating events
• Home care cases
• Outpatients/Office visits
• Hospitalizations
• Outbreaks
Cost categories
• Direct medical – Costs of medical 
personnel, facilities, diagnostics and 
medications for treatment
• Non-medical direct – Out-of-pocket 
costs for transportation and 
additional supplies usually paid by 
families
• Indirect – Costs of lost time from 
work or reduced productivity among 
caregivers or patients
• Infection control – Direct cost of 
additional institutional infection 
control measures
FIGURE 1. Cost-generating rotavirus events and cost categories.
ECONOMIC EVALUATION OF VACCINATION
Economic burden information is useful in describing
the extent of RVGE as a problem for families, the health care
system and society as a whole. However, additional informa-
tion is needed to compare the costs and benefits of vaccina-
tion. Several approaches are used for economic evaluation of
vaccines. They all provide a systematic way of comparing the
net costs of vaccination with the expected benefits.
In general, there are 2 basic approaches. A “cost ben-
efit” analysis compares the net monetary costs of vaccination
with the net monetary benefits of vaccination. The results can
be expressed as net costs or as the ratio of benefits to costs.
On the other hand, in the “cost effectiveness” analysis, the
incremental costs of vaccination are compared with the health
gains (expressed as cases, lives saved or a health metric such
as QALYs).
How would each be used to evaluate RV vaccination?
The paper by Takala et al is the only published example of an
economic evaluation of RV vaccination in a European set-
ting.9 The study examines the economic outcomes observed
in a clinical trial of the Rotashield vaccine (Wyeth, Colle-
geville, PA) in Finland. The study included the medical,
indirect and nonmedical direct costs of hospital and outpa-
tient visits in the placebo and vaccine arms of the clinical
trial. By comparing the costs for the 2 groups, they estimated
the costs averted through vaccination. They found that the
mean cost (direct and indirect) per child in the vaccinated
group was $0.72, compared with $40.32 in the placebo group,
demonstrating a significant reduction in the RV-related costs.
They also estimated that at a cost of $19.60 per child these
averted costs would offset the cost of vaccination (break-
even cost).9
A study by Tucker et al12 in the United States took a
similar approach but based the analysis on a model of the
expected outcomes in an annual birth cohort, rather than the
comparison of arms of a vaccine trial. The modeling ap-
proach used by Tucker et al12 has the advantage of using
representative epidemiologic, cost and efficacy data to esti-
mate vaccine costs and benefits before the introduction of the
vaccine. The advantage of the prospective approach used by
Takala et al9 is that it allows for the estimation of actual costs
of vaccinated and unvaccinated children. In addition, the
Takala study includes empirical estimates of productivity
losses while the paper by Tucker et al12 does not.
Both types of cost benefit analysis that focus on the
economic consequences of vaccination can be helpful to
decision makers. If the costs of vaccination were less than
medical costs averted, it would be cost-saving to the health
care system, making it an excellent investment that saves
money and improves health. If costs of vaccination were less
than the societal costs averted (medical direct, nonmedical
direct and indirect), then vaccination would make financial
sense for society as a whole, although it may require a net
investment from the health care system.
However, for the decision makers, the challenge arises
when the costs of vaccination are greater than averted costs.
This does not mean that vaccination is not appropriate but
that societal and health care resources must be invested to
reduce the risk of infection and improve children’s health. As
for most health interventions, a new approach does not need
to be cost-saving to be cost-effective.
Cost benefit analyses can capture the expected reduc-
tion in RV morbidity and mortality resulting from vaccina-
tion. However, they do so by estimating the monetary value
of these health improvements, based on either the human
capital approach (lost productivity from premature mortality)
or society’s willingness to pay to prevent a RV case or death.
In practice, many decision makers are hesitant to use the
approach of monetizing health gains.
Cost effectiveness analyses compare the net costs of
vaccination (usually from the health care system perspective)
to some measure of the health improvement from vaccination
such as deaths averted, life-years saved or QALYs gained.
This can be used to assess the efficiency of an intervention in
obtaining a specific benefit or to assess the value of the
intervention in relation to some standard of a “good invest-
ment.” Depending on the purpose, different health measures
may be used. The cost per case avoided may be useful in
comparing delivery strategies for the same vaccine (universal
versus targeted). The cost per death averted or cost per
life-year saved is often used to evaluate these vaccines for
which the primary outcome is mortality reduction. However,
when a vaccine is expected to reduce mortality and morbid-
ity, some measure of improvement that captures both is
required. QALYs are increasingly being used to evaluate
vaccines and other interventions that reduce both morbidity
and mortality. Studies that use QALYs as the main health
outcome are often referred to as cost-utility analyses.
QALYs measure health based on the duration of time
lived at different quality of life, using a 0–1 scale, in which
0 is death and 1 is perfect health. Mortality (or its prevention)
is captured based on the duration of time and the quality of
life that would have been experienced. Similarly morbidity is
based on the reduction in quality and the duration of the
event. Both are expressed as life-years. Although several
approaches are used for estimating QALY weights, they are
intended to reflect societal valuation of specific types of
morbidity in comparison with changes in duration of life or a
risk of death. As such, they provide a combined measure of
mortality and morbidity that captures a wide range of vaccine
benefits.
Several approaches are commonly used to estimate the
QALY weight for a specific condition on the 0–1 scale. In
direct elicitation studies, individuals with the condition (or
those very familiar with it) are asked how they would trade
off living with the condition and either a change in life
expectancy (time tradeoff) or a risk of death (standard gam-
ble). The second common approach is to use standardized
health classification instruments. In this approach, respon-
dents are asked to characterize a specific condition, based on
specific health domains. For example, the EQ-5D13 instru-
ment uses the domains of mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. For each domain
there are 3 levels of severity. An individual respondent can
rank a condition by the level of each domain. A “score” is
then based on standardized weights for each level, as deter-
mined in large population studies of preferences for the
different health states. Validated versions of the EQ-5D are
available for most European countries. Other similar instru-
ments include the Health Utilities Index (HUI; 3 versions).
The advantage of these standardized health classification
systems is that they generate comparable estimates for dif-
ferent conditions and are not prohibitively difficult to imple-
ment. The application of these methods to estimate QALYs
associated with vaccine-preventable diseases is discussed in
more detail below.
ECONOMIC EVALUATION OF OTHER
VACCINES OR VACCINATION STRATEGIES
IN EUROPE
Despite the lack of published economic evaluations of
RV vaccination in Europe, evaluations of other vaccinations
in Europe provide useful examples of the kinds of economic
information that could help decision makers in weighing RV
vaccination.
A number of studies use cost benefit analysis to com-
pare the costs of vaccination to the averted costs resulting
from vaccination.14–18 Many of the studies included both
direct medical and indirect costs, allowing for the calculation
of net benefits from the health care system and societal
perspectives. Many of these studies also include additional
analyses such as a cost-effectiveness analysis. For example,
Asensi et al14 estimated that use of the 7-valent pneumococ-
cal conjugate vaccine (PCV-70) in Spain would save a total
of 81 million euros over 10 years, of which 43.5 million euros
would be direct medical expenses. Vaccination would be
cost-saving from the societal perspective (including produc-
tivity losses) at a cost per dose of 56.87 euros per dose.
A small group of studies include cost effectiveness anal-
yses of bacillus Calmette-Guérin, influenza and hepatitis A and
B vaccination that use cost per case or event averted.19–22 In
most instances, these studies compare alternative vaccination
targeting strategies to identify the most efficient strategy for
preventing a specific outcome. For example, Hersh et al19
compare the cost effectiveness of universal versus targeted
tuberculosis immunization in Finland, and Szucs et al22
compare the cost effectiveness of hepatitis A and B vaccina-
tion in different age groups in Germany. Vaccination of 11-
to 15-year-olds was more cost-effective than vaccination of
all children younger than 15 years of age.22 However, the
limitation of the approach is that it does not allow evaluation
of whether vaccination of younger children would also be a
good health investment as a national strategy (even if it is not
as cost-effective as vaccinating the older group).
Several studies evaluate vaccination cost effectiveness
in terms of lives or life-years saved.14–16,23–30 This includes
several studies of pneumococcal vaccines that focus on the
health benefits associated with reduced mortality,14,16,23,25,27
as well as pertussis29 and hepatitis B.26 These analyses
address vaccines that primarily affect mortality or focus only
on the mortality impact of the vaccine. Extreme caution must
be used in interpreting these results because they are not
directly comparable. Studies differ by the age of the popula-
tion studied and have been conducted in different country
settings, which could affect vaccination effectiveness. In
addition, very different assumptions were used about vaccine
prices directly affecting the cost effectiveness ratio. This
precludes comparing the relative cost effectiveness of the
different vaccines. In many cases, the vaccines being evalu-
ated would also result in reductions in morbidity; however,
these benefits would not be captured with lives or life-years
saved as a measure of benefit.
A growing number of studies of the cost effectiveness
of vaccination use QALYs as the measure of health benefit,
allowing the consideration of both morbidity and mortality
benefits of vaccination (Table 2). These include studies of
pneumococcal vaccines23,25,30,33,35,38 as well as varicella,32,34
Haemophilus influenzae type b disease36 and meningitis.28,40
In addition, several studies have assessed the QALY impact of
specific vaccine-preventable diseases, such as meningitis.40
Although these studies share the use of QALYs to
capture morbidity and mortality prevention benefits of vac-
cination, they differ in several important ways (Table 2).
Most notably, they differ in the way that QALY weights are
determined. Assessing QALYs associated with vaccine-pre-
ventable illnesses in children by the usual methods described
above is often challenging because of the age of the patients.
Brisson and Edmunds32 estimate the QALY losses associated
with varicella and the cost effectiveness of vaccination
against it. In this study, parents of healthy children were
asked to rate the health of a child with chickenpox using the
HUI Mark 2 survey.41 QALY weights were calculated based
on the standardized scoring algorithm that provides a score
based on the combination of levels in each health domain and
population based estimates of preferences for them.41 The
QALYs lost for each condition were calculated by multiply-
ing the change in QALY weight (compared with a healthy
child) by the estimated duration of illness. Oostenbrink et al40
use a similar approach to estimate the QALYs associated with
meningitis symptoms using 3 health classification systems
(EQ-5D and HUI Mark 2 and 3).13,41,42 A panel of pediatri-
cians was asked to classify a variety of symptoms (deafness,
mild hearing loss, epilepsy, mild mental retardation, severe
mental retardation with tetraplegia, paresis of the leg and
mild retardation with epilepsy and paresis) according to the
questionnaires. QALY weights were calculated for each con-
dition with the standardized scoring algorithms for each. The
estimated QALY weights differed somewhat depending on
which instrument was used. Each of the health classification
systems use slightly different domains of health and thus are
sensitive to different aspects of a condition. By use of
alternative estimates of these weights, sensitivity analyses
can determine the effect on the overall outcome.
The studies also differ in the types of nonfatal outcomes
they consider. In particular, several studies only include
severe long term health outcomes,22,31–33,35–39 whereas oth-
ers also include short term transitory conditions.26,32,34,40
In addition to providing decision makers with a method
for comparing the cost effectiveness of different vaccines, a cost
effectiveness analysis based on QALYs also provides a way to
compare vaccines to decision makers’ notions of how much they
are willing to pay for a specific QALY improvement.
EVALUATING THE HEALTH BENEFITS OF RV
VACCINATION WITH QALYS
This growing literature on the cost effectiveness of
vaccination based on QALYs has important implications for
the consideration of RV vaccination in Europe. RV causes
extensive short term morbidity, whereas the mortality (al-
though very difficult to quantify) is probably very low in
Western Europe but higher in Eastern European countries.
Weighing the health benefits of vaccination against its costs
requires a measure like QALYs that accounts for reductions
in both morbidity and mortality.
There are several challenges to estimating the QALY
impact of RVGE and the benefits of vaccination. The first is
how to estimate the appropriate weight for a day with RVGE.
There are no published empirically established values in
Europe or elsewhere. A study by the United States Institute of
Medicine used a QALY weight of 0.25 (on a scale of 0–1),
based on authors’ opinions rather than being empirically
derived.43 Developing empirical estimates of the quality of
life impact of RVGE is particularly difficult because the
affected children are typically too young to respond to sur-
veys used to develop QALY weights.
Evaluation of varicella vaccination by Brisson and
Edmunds32 and the Oostenbrink et al40 study of meningitis
use proxy assessments based on existing standard health
status instruments, such as the EQ-5D and Health Utilities
Index. The studies used either parents or physicians as the
respondents to assess a wide range of chronic and transitory
conditions from chickenpox to hearing loss. The same ap-
proach could be used to assess the QALY weights for
different severities of RVGE (hospitalization, outpatient vis-
its and cases treated at home). For each severity level, parents
and/or physicians could be asked to rate the child’s health
using one of the standardized instruments. Separate ratings
could also be developed for children of different ages. The
domains of health included in the instruments are intended to
apply to a broad range of health outcomes and are not specific
to RV or pediatric patients. However, the calculated QALY
weights can be adapted to RV and adjusted by excluding
irrelevant domains.
Although QALYs provide a useful measure that cap-
tures mortality and morbidity, they have several limitations in
their application to childhood vaccines. Most notably, the
diverse severity of illnesses and the fact that they occur in
children make it difficult (if not impossible) to measure
QALY weights in the most methodologically rigorous man-
ner. This is also true for RV where several inherent limita-
tions include the lack of an instrument designed specifically
for pediatric applications and the common need to rely on
proxy respondents. Nevertheless several things can be done
to assess the internal validity of QALY estimates developed
in this way. These include: comparing responses of different
TABLE 2. Studies Using Quality-Adjusted Life Years (QALYs) to Evaluate Interventions Against Vaccine Preventable
Diseases
Author Vaccine Intervention Country Population Outcomes Included Method of QALYEstimation
Bos,23 2003 Pneumococcal (7-valent) Netherlands Infants Mortality, severe long
term sequelae
Published estimates and
author mapping to EQ-5D
Bos,31 2001 Pneumococcal (7-valent) Netherlands Infants Mortality, severe long
term sequelae
Published estimates and
author mapping to EQ-5D
Brisson,32 2003 Varicella England and Wales Infants Varicella, zoster HUI Mark 2 in parents
De Graeve,33 2000 Pneumococcal (23-valent) Belgium Elderly Mortality, invasive
pneumococcal
disease
Published estimates and
author assumptions
Edmunds,34 2001 Herpes zoster England and Wales Various Zoster HUI Mark 2 in parents
Ess,35 2003 Pneumococcal Switzerland Infants Mortality, severe long
term sequelae of
meningitis
Literature, author
assumptions
Livartowski,36 1996 Haemophilus influenzae France Children Permanent sequelae
of Hib invasive
disease
Expert opinion, and Gudex
and Kind classification
system
Melegaro,27 2004 Pneumococcal England and Wales Infants Mortality, hearing
loss, seizures,
bacteremia,
pneumonia, otitis
media
Published literature
Oostenbrink, 200237 Meningitis treatment Netherlands Children with
meningeal
signs
Mortality, long term
sequelae
Published literature
Plans Rubio,38 1995 Pneumococcal Spain Older than 5
yr old
Mortality, long term
sequelae
Authors’ assumptions
Ruedin,39 2003 MenC and MenC/PCV-9 Switzerland Various Mortality, moderate
and severe long
term complications
Expert panel and HUI
Mark 2
Oostenbrink, 200240 Meningitis diagnosis Netherlands Children with
meningeal
signs
Deafness, mild
hearing loss,
epilepsy mental
retardation, paresis
of the leg
EQ-5D, HUI Mark 2, HUI
Mark 3 in pediatricians
Hib indicates Haemophilus influenzae type b; MenC, Neisseria meningitidis C.
proxy groups (parents and physicians); comparing the esti-
mated weights based on clinical severity; and comparing
estimates using multiple instruments. In the presence of this
kind of uncertainty, economic analyses routinely use sensi-
tivity analyses to determine the potential impact of these
uncertain values on the robustness of the results. Using this
approach, decision makers can include the morbidity reduc-
tion benefits of vaccination, without overstating them.
Although the QALY approach will remain subject to
these uncertainties, it provides an important (albeit imper-
fect) measure of health benefit that decision makers can
weigh against the net costs of vaccination in a specific
country. Without a method for quantifying these nonfatal
health benefits (such as the QALYs), economic evaluations
of vaccination in low mortality settings will be based only
on the financial costs and economic benefits. This under-
estimates the real public health benefit of morbidity-reduc-
ing vaccines such as those for RVGE, especially in
wealthy settings, such as Europe. The methods for the
economic evaluations of vaccines that reduce mortality
and improve quality of life will continue to develop, and
QALYs will continue to be an important tool for providing
decision makers with quantifiable measures of health ben-
efit that can be systematically compared with both costs
and to other vaccinations.
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